The Mymee Method

Why Personalized Trials

Managing hidden triggers in the real world

Patients with autoimmune diseases often are able to use one or more prescription therapies called immunosuppressants to gain control of their disease flares. Such therapies have made great strides in helping patients improve their quality of life by reducing the immune system's response to triggers hidden in their exposome.

Non-responders to such therapies remain vulnerable to the complex variables that make up their exposome. Their immune system continues to inflame and attack different cell types throughout their body, resulting in such uncontrolled symptoms as pain and inflammation in multiple joints, weakness, brain fog, digestive issues, sleep disorders, headaches and more.

What is a non-responder?

A non-responder is someone who cannot tolerate their prescribed immunosuppressant or sees only minimal improvement in rheumatic symptoms, like joint pain or stiffness despite treatment. On average 40% of patients in randomized controlled trials are non-responders.

What is the exposome?

The exposome represents the totality of all internal biological and external environmental factors individuals are exposed to throughout their life. Such factors can include diet, sleep, stress, air and water quality, climate and exposure to mold, toxins, pathogens or UV light.

No two exposomes are the same, not even with identical twins.

It can be a perfect storm of triggers that lead to a deterioration in health. The type, timing and frequency of exposures to potential triggers all play a role.

Managing flares through trial & error

For people with unpredictable and debilitating symptoms, trial & error between additional medications, supplements and diets can lead to even more exposure to hidden triggers, with no way to know what helps and what hurts.

Understanding how hidden triggers, cross-reactivities, and interactions in the exposome, directly impact one's own symptoms, is critical to preventing and managing flares.

How it Works

From trial & error to personalized trial & care

Mymee replaces the difficult and often dangerous trial & error process with personalized trial & care.

A self-evidence-based approach is critical to being able to directly correlate symptoms to unique triggers hidden within the exposome.

Mymee pairs each patient with a certified personalized trial coach who guides every step of the process with one-to-one support.

Our research

One-to-One Support

Mymee Coach Expertise

Mymee coaches are certified health and nutrition experts trained on Mymee’s proprietary personalized trial & care platform to analyze unique trigger-symptom correlations and guide each person through their own personalized trial process.

Each coach has experience reclaiming their own health from autoimmune disease and brings deep knowledge and training helping patients gain control of unpredictable flares.

Mymee personalized trial & care expertise:

Outcomes & Research

Who may benefit from personalized trials

Mymee’s personalized trial & care platform is clinically validated for patients with unmanageable symptoms and complex sensitivities to their exposome, resulting from ≥1 autoimmune disease or long COVID.

Enrolled patients reported a mean improvement across 59 patient-reported symptoms of 40% in an average of 17 weeks.

Patients with moderate to severe symptoms achieved statistically significant and clinically meaningful improvement across all ten HRQoL PROMIS^Ⓡ domains.

In peer-reviewed studies of personalized trials, the mostly commonly reported symptoms at enrollment included*:

Fatigue
Pain & aches in joints
Limitation of movement
Feeling of weakness
Pain or cramps in muscles
Diarrhea and/or constipation
Night waking
Brain fog (poor memory, confusion)
Anxiety
Headaches
Faintness/dizziness
Numb or tingly sensation
Intestinal or abdominal pain
Breathing difficulties
Tremor or restless leg

The most frequent diseases in the studies included:

Rheumatoid Arthritis
Lupus (SLE)
Psoriatic Arthritis
Ankylosing spondylitis
Long COVID
Mixed connective tissue disease
Crohn’s and ulcerative colitis plus rheumatic symptoms
Psoriasis plus rheumatic symptoms
Multiple sclerosis plus rheumatic symptoms

Additional research and analysis has demonstrated that personalized trials and care with Mymee has enabled patients to:

Improve their ability to work with their doctor to manage symptoms
Achieve statistically significant improvements in ten health-related quality of life (HRQoL) domains such as fatigue, pain, anxiety and cognitive function
Improve their feelings of hopelessness by an average of 75%

*Sources: 1. Peer-reviewed study of personalized trials in autoimmune population, Rheumatic & Musculoskeletal Open Journal, May 2023; 2. Symptoms-59 survey, weighted mean change (n=182 personalized trials); 3. A Self-Evidence-Driven Personalized Trial and Care Program Correlates the Exposome to Persistent Autoimmune Rheumatic Symptoms and Improves Health-Related Quality of Life; (n=163 personalized trials); poster, IMF conference, 2023.

Mymee’s specialty is working with individuals who

Have one or more diagnosed rheumatic autoimmune diseases such as Lupus, RA, Ankylosing Spondylitis, Psoriatic Arthritis or Mixed Connective Tissue Disease

Report active joint pain & other systemic rheumatic symptoms associated with rheumatic long COVID & autoimmune diseases like Psoriasis, Inflammatory Bowel Disease or Hashimoto's

Managing > 10 unique unpredictable symptoms, not unusual with long COVID & mixed autoimmune disease diagnosis

Are adhering to presciption NSAIDs, steroids, conventional and/or biologic DMARDS & still experiencing disease flares

Already tried supplements, autoimmune diets & removing gluten, and are still managing significant unpredictable sysmptoms

Are at a crossroads with their treatment & working with their doctor to decide what's next